Circulating non-coding RNAs in recurrent and metastatic ovarian cancer

Cancer Drug Resist. 2019 Sep 19;2(3):399-418. doi: 10.20517/cdr.2019.51. eCollection 2019.

Abstract

Ovarian cancer has a poor outcome because it is usually detected at advanced tumor stages, and the majority of the patients develop disease relapse as a result of chemotherapy resistance. This most lethal gynecological malignancy metastasizes within the peritoneal fluid or ascites to pelvic and distal organs. In ovarian cancer progression and metastasis, small non-coding RNAs (ncRNAs), including long noncoding RNAs and microRNAs have been recognized as important regulators. Their dysregulation modulates gene expression and cellular signal pathways and can be detected in liquid biopsies. In this review, we provide an overview on circulating plasma and serum ncRNAs participating in tumor cell migration and invasion, and contributing to recurrence and metastasis of ovarian cancer. We will also discuss the development of potential, novel therapies using ncRNAs as target molecules or tumor markers for ovarian cancer.

Keywords: Ovarian cancer recurrence; chemotherapy; epithelial-mesemchmal transition; metastasis; non-coding RNAs; tumor markers.

Publication types

  • Review